JP2005514030A - Ｖｈおよびｖｌドメインから多重特異性多価薬剤を製造する方法 - Google Patents

Ｖｈおよびｖｌドメインから多重特異性多価薬剤を製造する方法 Download PDF

Info

Publication number
JP2005514030A
JP2005514030A JP2003558131A JP2003558131A JP2005514030A JP 2005514030 A JP2005514030 A JP 2005514030A JP 2003558131 A JP2003558131 A JP 2003558131A JP 2003558131 A JP2003558131 A JP 2003558131A JP 2005514030 A JP2005514030 A JP 2005514030A
Authority
JP
Japan
Prior art keywords
binding
binding protein
polypeptide
binding site
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003558131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514030A5 (enExample
Inventor
エドムンド、ロッシー
チェーン‐シン、ケン、チャン
デイビッド、ゴールデンバーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
IBC Pharmaceuticals Inc
Original Assignee
Immunomedics Inc
IBC Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc, IBC Pharmaceuticals Inc filed Critical Immunomedics Inc
Publication of JP2005514030A publication Critical patent/JP2005514030A/ja
Publication of JP2005514030A5 publication Critical patent/JP2005514030A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2003558131A 2001-12-26 2002-12-26 Ｖｈおよびｖｌドメインから多重特異性多価薬剤を製造する方法 Withdrawn JP2005514030A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34210301P 2001-12-26 2001-12-26
PCT/US2002/038985 WO2003057829A2 (en) 2001-12-26 2002-12-26 Methods of generating multispecific, multivalent agents from vh and vl domains

Publications (2)

Publication Number Publication Date
JP2005514030A true JP2005514030A (ja) 2005-05-19
JP2005514030A5 JP2005514030A5 (enExample) 2006-02-23

Family

ID=23340336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003558131A Withdrawn JP2005514030A (ja) 2001-12-26 2002-12-26 Ｖｈおよびｖｌドメインから多重特異性多価薬剤を製造する方法

Country Status (12)

Country Link
US (1) US20030162709A1 (enExample)
EP (1) EP1468097A4 (enExample)
JP (1) JP2005514030A (enExample)
KR (1) KR20040091616A (enExample)
AU (1) AU2002364531A1 (enExample)
BR (1) BR0215403A (enExample)
CA (1) CA2471868A1 (enExample)
IL (1) IL162732A0 (enExample)
MX (1) MXPA04006327A (enExample)
PL (1) PL372144A1 (enExample)
RU (1) RU2004122702A (enExample)
WO (1) WO2003057829A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513476A (ja) * 2014-04-13 2017-06-01 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ 三機能性抗原結合分子
JP2018537415A (ja) * 2015-10-13 2018-12-20 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ 多価Ｆｖ抗体

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
IL161417A0 (en) * 2001-10-15 2004-09-27 Immunomedics Inc Affinity enhancement agents
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
JP4874090B2 (ja) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物
US20050003403A1 (en) * 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
CN1326881C (zh) * 2003-09-29 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 一种三价双特异性抗体，其制备方法及用途
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
JP5377965B2 (ja) 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
WO2007030802A2 (en) * 2005-09-09 2007-03-15 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
EP2500360B1 (en) 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US8481272B2 (en) 2006-08-04 2013-07-09 Georgia State University Research Foundation, Inc. Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity
EP2097507B1 (en) 2006-12-14 2015-05-06 Georgia State University Research Foundation, Inc. Analyte sensors and use thereof for detecting analyte activity
WO2009146099A2 (en) 2008-04-02 2009-12-03 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
US9956304B2 (en) 2012-06-05 2018-05-01 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
US11571476B2 (en) 2017-12-11 2023-02-07 Taipei Medical University Anti-tumor/anti-tumor associated fibroblast/anti-hapten trispecific antibodies and use thereof
TWI870708B (zh) * 2017-12-12 2025-01-21 臺北醫學大學 多特異性抗體及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088994B1 (en) * 1982-03-15 1991-06-19 Schering Corporation Hybrid dna, binding composition prepared thereby and processes therefor
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
CA2145278C (en) * 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US6254868B1 (en) * 1996-03-20 2001-07-03 Immunomedics, Inc. Glycosylated humanized B-cell specific antibodies
WO1997038102A1 (en) * 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US7074405B1 (en) * 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513476A (ja) * 2014-04-13 2017-06-01 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ 三機能性抗原結合分子
JP2018537415A (ja) * 2015-10-13 2018-12-20 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ 多価Ｆｖ抗体

Also Published As

Publication number Publication date
US20030162709A1 (en) 2003-08-28
AU2002364531A1 (en) 2003-07-24
EP1468097A4 (en) 2006-01-11
MXPA04006327A (es) 2005-07-13
IL162732A0 (en) 2005-11-20
CA2471868A1 (en) 2003-07-17
BR0215403A (pt) 2005-05-03
KR20040091616A (ko) 2004-10-28
WO2003057829A3 (en) 2004-02-26
PL372144A1 (en) 2005-07-11
RU2004122702A (ru) 2005-04-20
WO2003057829A2 (en) 2003-07-17
EP1468097A2 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
US20030162709A1 (en) Methods of generating multispecific, multivalent agents from VH and VL domains
JP7828375B2 (ja) 標的分子に対する抗原結合コンストラクト
Kipriyanov et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
CA2555503C (en) Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto
US8829175B2 (en) Nucleic acids encoding polyvalent protein complexes
AU2003209447B2 (en) RS7 antibodies
US20030148409A1 (en) Direct targeting binding proteins
JP2005526044A5 (enExample)
Gao et al. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein× anti-CD3 diabody
CN114195894B (zh) 一种靶向4-1bb的抗体及其应用
JP7812336B2 (ja) 分子連結法または分子工学のためのタンデムリピートがん標的化ペプチドおよびがんセラノスティクスにおけるその使用
US9611321B2 (en) Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies
JP2024531426A (ja) Ｃｄ１５５に対する抗体および抗原結合フラグメント、その使用方法
EP1444267B1 (en) Affinity enhancement agents
WO2023116781A1 (zh) 一种新型pd1单域抗体的开发
AU2002335808A1 (en) Affinity enhancement agents
CN121203011A (zh) 人源化抗α2δ1单克隆抗体及其应用
CN118480130A (zh) 靶向msln的抗体、嵌合抗原受体及其应用
AU2002348437A1 (en) Direct targeting binding proteins
Marlind et al. Tumor vascular targeting

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051226

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060822